Valneva's Chikungunya vaccine IXCHIQ® shows positive antibody persistence & safety in 304 children from Phase 2 trial. Future Phase 3 development planned for children after real-world experience in adolescents.
On December 10, 2025, in Saint-Herblain, France, Valneva SE, a specialty vaccine company (Nasdaq: VALN; Euronext Paris: VLA), shared positive final data from their Phase 2 clinical trial. The trial assessed the safety and immunogenicity of two dosage levels of their single-shot chikungunya vaccine, IXCHIQ®, in 304 children. The results, observed twelve months post-vaccination, highlighted favorable antibody persistence and safety profiles. This study, partially backed by the Coalition for Epidemic Preparedness Innovations (CEPI) and aided by support from the European Union, signifies progress towards Phase 3 trials in children. Valneva SE intends to commence Phase 3 trials after gaining more real-world insights from the adolescent population.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments